Discover our latest insights into the groundbreaking developments in neuroscience on how biomarkers are transforming the treatment of neurodegenerative diseases.
Key highlights include:
- The necessity of early biomarker strategy development to optimize the commercialization of disease-modifying therapies (DMTs).
- The pivotal role of biomarkers in the development and approval of recent Alzheimer’s therapies.
- Innovative biomarker technologies for Parkinson’s Disease, such as the promising seeding amplification assay (SAA).
- Recent regulatory validation of neurofilament light chain (NfL) as a blood-based biomarker for SOD-1 amyotrophic lateral sclerosis.
Disclaimer: “Drill Down & Catch Up” segments are not comprehensive but designed to deliver topical information and stimulate thought and discussion. We welcome your comments and opportunities to learn more about your neuroscience programs.
Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.
